Ellipsis Health's Sage is an AI-based care manager that conducts automated voice interactions to complete care-management workflows, performs vocal-biomarker analysis for screening and monitoring of depression, anxiety, and stress, and integrates with enterprise health systems and CRM platforms to support high-volume outreach.
Published Oct 13, 2026
No detailed public roadmap was located in the reviewed materials. Buyers should request a roadmap and feature availability timelines during sales engagement.
The vendor does not publish concurrency, throughput, or large-scale performance constraints publicly; these are important items to verify for large outreach campaigns.
Ellipsis Health does not appear to have a well-established footprint on major B2B SaaS review platforms under an obvious listing name in this research session. This limits the availability of independent, crowdsourced validation.
The vendor’s homepage includes partner and customer-style quotes, for example:
These are vendor-published testimonials and should be treated as vendor-provided input rather than independent verification.
An app-store listing for a consumer-facing Ellipsis app shows minimal review volume and indicates limited privacy practice disclosures in that listing. This listing appears to have limited relevance to the enterprise Sage deployments.
Third-party review aggregators display mixed and low-confidence comments; the content and provenance of those reviews are uncertain and should be treated with caution.
High-signal community posts referencing operator-level implementation experience were not surfaced in the searches performed. This reduces the amount of publicly available anecdotal implementation feedback.
Likely drivers based on vendor materials and press coverage:
Vendor site content appears to include announcements and summary outcomes rather than detailed, independently validated case studies with transparent methodologies.
Some vendor or partner profiles reference ROI-style metrics and operational impact (example claims: multi-fold ROI, faster enrollments, and estimates of automation percentages). These claims are presented by third-party profile pages or vendor materials and do not include transparent methodologies or audited data; treat them as vendor-reported outcomes that require verification.
A peer-reviewed publication referenced by the vendor reports validation of depression detection performance on a dataset of real-world calls, with reported metrics such as correlation and AUC ranges. This supports that vocal-feature analysis can correlate with PHQ-style severity scores in that dataset, but it does not by itself prove clinical outcome improvements or generalize to all populations or use cases.
Request from the vendor:
Get a comprehensive analysis of Ellipsis Health including market position, competitive landscape, adoption trends, and peer benchmarks.
Download full report →You need transparent self-serve pricing and very fast procurement:
You require extensive third-party review validation:
Your primary use case is digital front door / patient access rather than care management:
You require independently validated biomarker performance across broad populations prior to pilot:
You want maximum control and have engineering bandwidth to build and own the system:
Sources:
Source:
Request the following from the vendor during diligence:
Source:
Given limited independent review content, these are risk hypotheses to validate during reference checks:
Sources:
Source:
Best-fit organizations typically have:
Because the vendor does not publish customer-count or ARR publicly, sizing is inferred from typical enterprise buyer profiles:
Ellipsis Health is a healthcare-focused AI company whose flagship product, Sage, is described by the vendor as an AI-based care manager that conducts automated voice interactions with patients/members to complete care-management workflows (for example: discharge follow-ups, health risk assessments, outreach, enrollment, medication adherence check-ins). The vendor refers to a proprietary vocal-biomarker model that is intended to infer emotional state from voice features and adapt interactions accordingly.
Ellipsis also offers vocal biomarker analysis intended to support screening and monitoring for depression, anxiety, and stress from short voice samples and from clinical calls, including support for PHQ-style scoring in care management contexts.
Key product claims/features (vendor-published, presented objectively):
Sources:
Target buyers: healthcare payers (health plans), providers (health systems), and care management organizations that run high-volume outreach and assessments—especially populations with complex needs (behavioral + medical + social).
Positioning: The vendor positions Sage as a tool intended to increase care management capacity through automated voice interactions with emotion analysis, rather than as a generic IVR solution. The vendor asserts differentiation based on the vocal biomarker model and clinical oversight.
Sources: